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ses on a new product’s adverse event rate and failure rate can 
be used to trace “iso-cost” and “iso-QALY” curves depicting
combinations of these parameters yielding equivalent costs and
QALYs, respectively, compared to an existing standard of care.
RESULTS: Graphical analyses of the iso-cost and iso-QALY
curves highlight four distinct regions of parameter combinations
in which a new product would be dominant, incrementally cost-
effective (at a given threshold), incrementally cost-ineffective, or
dominated. Prior probability distributions on these parameters
can be used to predict the likelihood of being in each of these
regions, and value-of-information analysis can be used to assess
formally the expected net beneﬁt of proceeding with clinical
development, reﬂecting the present value of its future revenue
stream less the total costs of bringing it to market. Modeling per-
formed in psychiatry will be used to illustrate the concepts.
CONCLUSIONS: Methods for “go/no-go” modeling of com-
pounds in the development pipeline provide a means of incor-
porating pharmacoeconomic criteria into drug development
decision-making.
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OBJECTIVES: To assess the impact various price control 
mechanisms (PCM), including re-importation, would have on
the incentives for R&D investment in the pharmaceutical and
biotechnology industries. METHODS: A simulation model,
based on the most recently compiled estimates of the costs and
returns to R&D investment in the pharmaceutical industry is
used to estimate the distribution of expected NPV at the time
products enter clinical testing. The model estimates the impact
of various PCMs on this distribution, and on the resulting R&D
investment ($ and % age) that meet the necessary NPV > 0
threshold. RESULTS: Under the naïve model of no project spe-
ciﬁc information, the model shows that there would be little
impact of implementing price controls if ﬁrms could be assured
that these controls would not reduce prices by more than 25%.
However, preliminary results show that if ﬁrms believed that
price controls would exceed this threshold, they would suspend
all investment in new R&D projects. Under more realistic
assumptions, the impact of even mild price controls leads to an
immediate cut-backs in R&D projects as marginal projects are
eliminated. An anticipated 25% reduction in future US prices
would decrease R&D project by approximately 50% and R&D
investment by approximately 33%. CONCLUSIONS: Our sim-
ulation model shows that pharmaceutical industry investment in
R&D is very sensitive to price controls in the US.
